Glenmede Trust Co. NA Sells 5,218 Shares of Labcorp Holdings Inc. $LH

Glenmede Trust Co. NA lowered its holdings in shares of Labcorp Holdings Inc. (NYSE:LH) by 2.0% in the first quarter, Holdings Channel.com reports. The fund owned 261,012 shares of the medical research company’s stock after selling 5,218 shares during the quarter. Glenmede Trust Co. NA’s holdings in Labcorp were worth $69,641,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the business. Western Wealth Management LLC bought a new position in Labcorp in the 1st quarter worth about $130,000. Oddo BHF Asset Management Sas raised its stake in shares of Labcorp by 4.2% during the first quarter. Oddo BHF Asset Management Sas now owns 18,992 shares of the medical research company’s stock valued at $5,067,000 after acquiring an additional 768 shares in the last quarter. Amundi raised its stake in shares of Labcorp by 14.3% during the first quarter. Amundi now owns 274,184 shares of the medical research company’s stock valued at $73,155,000 after acquiring an additional 34,351 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Labcorp by 55.2% in the first quarter. EverSource Wealth Advisors LLC now owns 1,937 shares of the medical research company’s stock valued at $517,000 after purchasing an additional 689 shares during the period. Finally, Royal Bank of Canada grew its stake in Labcorp by 19.4% in the first quarter. Royal Bank of Canada now owns 820,442 shares of the medical research company’s stock worth $218,901,000 after purchasing an additional 133,549 shares in the last quarter. Institutional investors own 95.94% of the company’s stock.

Labcorp Price Performance

NYSE LH opened at $309.47 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.54 and a current ratio of 1.80. The firm’s 50 day moving average price is $274.71 and its 200-day moving average price is $271.01. Labcorp Holdings Inc. has a 52-week low of $244.52 and a 52-week high of $316.11. The company has a market cap of $25.38 billion, a PE ratio of 25.60, a P/E/G ratio of 2.09 and a beta of 0.89.

Labcorp (NYSE:LH) last issued its quarterly earnings data on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, topping analysts’ consensus estimates of $4.78 by $0.21. The company had revenue of $3.73 billion during the quarter, compared to the consensus estimate of $3.71 billion. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. Labcorp’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.35 earnings per share. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Sell-side analysts forecast that Labcorp Holdings Inc. will post 18.04 EPS for the current fiscal year.

Labcorp Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 28th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Friday, August 28th. Labcorp’s dividend payout ratio is 25.51%.

Analysts Set New Price Targets

Several research firms have commented on LH. Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Weiss Ratings upgraded Labcorp from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $306.00 price target on shares of Labcorp in a research report on Friday. Morgan Stanley raised their price target on Labcorp from $308.00 to $338.00 and gave the company an “overweight” rating in a research note on Friday. Finally, Barclays lifted their price objective on Labcorp from $290.00 to $320.00 and gave the company an “equal weight” rating in a report on Thursday. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $323.27.

Labcorp News Summary

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Labcorp exceeded expectations in the second quarter, reporting adjusted EPS of $4.99 versus the $4.78 analyst consensus and revenue of $3.73 billion versus estimates of $3.71 billion. Revenue increased 5.8% year over year, supported by steady diagnostic-testing demand and growth in drug-development services. Reuters article
• Positive Sentiment: The company raised its 2026 adjusted EPS guidance to $18.10-$18.55, above the roughly $17.99-$18.00 consensus, while forecasting revenue of approximately $14.71 billion-$14.83 billion. Diagnostics Laboratories revenue rose 5.5%, and Biopharma Laboratory Services revenue increased 6.5%. Labcorp second-quarter results
• Positive Sentiment: Labcorp expanded its share-repurchase authorization by $1 billion, repurchased $353.8 million of stock during the quarter and paid $58.7 million in dividends. Truist Financial also raised its price target from $320 to $350 and assigned a “buy” rating, implying further upside from recent levels. Benzinga reference
• Neutral Sentiment: Management highlighted continued investment in oncology, consumer health and technology initiatives. The earnings call transcripts provide additional detail on demand trends, margins and the updated outlook. Labcorp Q2 earnings call transcript
• Negative Sentiment: Despite the earnings and revenue beats, LH shares fell in premarket trading and remain lower in active trading. The reaction indicates that investors may have viewed the results and raised outlook as insufficient relative to elevated expectations and the stock’s recent rally toward its 52-week high. Zacks market reaction
• Negative Sentiment: Recent insider-trading data shows company insiders made multiple sales and no purchases over the past six months, a potential sentiment headwind, although the transactions do not necessarily reflect management’s outlook. Quiver Quantitative report

Insider Activity at Labcorp

In other Labcorp news, CEO Adam H. Schechter sold 5,903 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $254.50, for a total value of $1,502,313.50. Following the completion of the transaction, the chief executive officer directly owned 107,234 shares in the company, valued at approximately $27,291,053. The trade was a 5.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Bryan T. Vaughn sold 234 shares of the stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total transaction of $66,968.46. Following the sale, the executive vice president directly owned 6,746 shares of the company’s stock, valued at approximately $1,930,637.74. The trade was a 3.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 6,991 shares of company stock valued at $1,796,696 over the last quarter. 0.84% of the stock is owned by corporate insiders.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.